Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial

Journal:

Nature Medicine

Published:

2025-10-06

DOI:

10.1038/s41591-025-03971-6

Affiliations:

14

Authors:

15

Go to article

Institutions	Authors	Share
MoonLake Immunotherapeutics, Switzerland	3.500000	0.23
University of Glasgow, United Kingdom (UK)	1.000000	0.07
University of Oxford, United Kingdom (UK)	1.000000	0.07
University of Pennsylvania (Penn), United States of America (USA)	1.000000	0.07
University of California, San Diego (UC San Diego), United States of America (USA)	1.000000	0.07
Womens College Hospital (WCH), U of T, Canada	1.000000	0.07
University of Erlangen-Nuremberg (FAU), Germany	1.000000	0.07
Altoona Center for Clinical Research, United States of America (USA)	1.000000	0.07
University of Leeds, United Kingdom (UK)	1.000000	0.07
University of Rochester (UR), United States of America (USA)	1.000000	0.07
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)	1.000000	0.07
Providence Swedish, United States of America (USA)	0.500000	0.03
University of Washington (UW), United States of America (USA)	0.500000	0.03
University Medical Center Hamburg-Eppendorf (UKE), UHH, Germany	0.500000	0.03

Interested in Clinical Sciences?